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Introduction
Data from observational and clinical studies have shown that dietary fat quality, rather than quantity, is more important in altering atherogenic blood lipids and influencing cardiovascular disease (CVD) risk [1] [2] [3] [4] . Traditionally, observational studies have mainly relied on self-reported dietary intake data, which are limited by e.g., reporting bias and inaccurate food databases.
However, the use of tissue fatty acid (FA) composition (e.g., in plasma fractions or adipose tissue) as biomarkers of dietary fat has increased in recent years. As most FAs are endogenously synthesized in humans, only a few can be considered reliable biomarkers of dietary fat composition. Among these are two very long-chain (VLC) n-3 polyunsaturated fatty acids (PUFA) of mainly marine origin, eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), as well as the two essential PUFA, linoleic acid (LA; 18:2n-6) andlinoleic acid (ALA; 18:3n-3), abundant in non-tropical vegetable oils. LA and, to lesser extent, ALA lower LDL cholesterol when replacing saturated fats 5 . However, ALA, unlike LA, may decrease HDL concentrations 5 . EPA and DHA on the other hand have potential anti-arrhythmic effects and may improve endothelial function 6 and lower blood pressure 7 and triglycerides 8 . Thus, different PUFA seem to have selective roles in the development of CVD, whereas possible influences on non-CVD outcomes are less clear 9 . Dietary intake of EPA, DHA, LA, and to a lesser extent ALA are reflected in the FA composition in serum cholesteryl esters (CE), and thus the proportions of these PUFA in CE can be utilized as biomarkers to assess the intake of the respective PUFA [10] [11] [12] . Accordingly, FA composition (especially EPA, DHA, and LA) in CE correlates well with self-reported FA intake in both Swedish 13 and other cohorts 14 .
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Furthermore, recent studies have reported inverse associations of both n-6 and n-3 PUFA in plasma phospholipid with all-cause and cause-specific mortality as well as incident CVD in a US cohort of older men and women 22, 23 .
This study investigated associations between biomarkers of PUFA intake (EPA, DHA, LA, and ALA) in serum CE and incident CVD and all-cause mortality in men and women, separately and combined, in a large population-based cohort.
Material and methods

Study population
The current cohort has been utilized for prospective studies on cardiovascular risk, as previously described 24 . In brief, a Swedish population register was used to identify all men and women living in Stockholm County who turned 60 between July 1, 1997 and June 30, 1998 . Invitations were sent out between August 1997 and March 1999 asking every third individual identified to participate in health screening, including blood sampling and completion of an extensive Furthermore, recent studies have reported inverse associations of both n-6 6 6 an an and d d n-n-n-3 3 3 PU PU PUF FA F n plasma phospholipid with all-cause and cause-specific mortality as well as incident CVD in a US c c coh oh ohor or ort t t of of of old d der er r men and women 22, 23 .
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Serum cholesteryl ester fatty acid measurement
Fatty acid composition in serum CE was measured by gas chromatography as described earlier 25 .
In brief, serum CE were methylated, extracted in petroleum ether, evaporated, and redissolved in hexane before analysis by gas chromatography with flame ionization detection. Thirteen different FA were quantified (14:0-22:6n3) and the proportion of each was expressed as a percentage of all measured FA. Fatty acid composition in one serum sample was repeatedly analyzed in duplicates in all batches for quality control and the intra-and interassay coefficient of variations were 0.24 and 2.49 %, respectively, for the fatty acids utilized for statistical
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Endpoint definition
The main outcomes, incident CVD and all-cause mortality, were identified using the Swedish Hospital Discharge and Cause of Death registers. Incident CVD comprised first-time ischemic CVD events including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, and hospitalization due to angina pectoris (International Classification of Disease 10 th revision (ICD-10) codes: I20, I21, I25, I46, and I63-I66). In order to elucidate whether potential associations between serum FA and all-cause mortality was determined by CVD-related deaths, CVD mortality was included as an additional outcome defined as death due to CVD (primary cause of death specified as ICD-10 codes I10-I99). All participants were followed up regarding incidence of CVD and death until December 31, 2012. Among participants with measured serum FA composition at baseline, 139 women and 229 men with prevalent CVD at baseline (selfreported or identified by register data) or uncertain disease history were excluded from further analyses.
Statistical analysis
Median and interquartile range (IQR) or mean and SD of FA proportions, blood lipids, blood glucose, blood pressure, and BMI were calculated separately for men and women. For skewed variables, Wilcoxon-Mann-Whitney test was utilized to assess differences between sexes 26 , while differences in frequencies of baseline characteristics were assessed by 2 -tests. For variables with normal distribution, sex differences in means were evaluated by two-tailed Student's t-test.
Relationships between the selected serum PUFA (EPA, DHA, LA, and ALA) were investigated associations between serum FA and all-cause mortality was determined by CVD--re re rela la late te ted d d de de deat at aths h h , by re re regi gi gist st ster er er da da data ta ta) ) ) or or or unc nc ncer er erta ta tain in in d d dis is isea ea ease se se h h his is ist t tor or ory we e were re re e e exc c xclu l lude de ded d d fr fr from om om f f fur r urth th ther er er by calculating Pearson's correlation coefficients.
Crude and multivariate-adjusted Cox proportional hazard models were employed to calculate hazard ratio (HR) and 95% CI for incident CVD and all-cause mortality in men and women separately and together. In the adjusted models, BMI, smoking, physical activity, education, alcohol intake, diabetes, drug-treated hypertension, and drug-treated hypercholesterolemia at baseline were included as covariates. Serum FA (EPA, DHA, LA, and ALA) were investigated as continuous (per 1-SD increase) and categorical (quartiles) variables.
The proportional hazard assumption was not violated according to the Schoenfeld residuals. To retain study power, missing indicator categories were used for missing covariates; the frequency of missing values in each covariate was <1%, and <3% of the study population had missing values in 1 covariate. In order to evaluate the impact of fish oil supplementation on associations of EPA and DHA with incident CVD and mortality, analyses of such associations were repeated after exclusion of participants with reported fish oil supplement use. Restricted cubic splines (mkspline command) with 5 knots (located at percentiles 5, 27.5, 50, 72.5, and 95) as previously suggested 27 were utilized for evaluation of potential nonlinear associations. Due to the low number of CVD-related deaths, analyses for CVD mortality were only performed on the total population. P<0.05 was considered significant. All statistical calculations were performed using STATA 11 (Stata Corporation, College Station, TX, USA).
Results
At baseline, men had slightly higher fasting glucose, fasting triglycerides, and blood pressure compared to women, who instead had somewhat higher concentrations of total and HDL cholesterol and serum ALA ( Table 1 ). In addition, the proportions of never-smokers, low/none-of missing values in each covariate was <1%, and <3% of the study population had ad ad m m mis is issi si sing ng ng consumers of alcohol (<1 drink/week), and non-diabetics were greater among women, while men were more physically active ( Table 1 ). The use of fish oil supplementation was low (1%) and did not differ between men and women.
No differences between men and women were observed at baseline for the serum LA and EPA, while median serum CE proportions of ALA and DHA were greater in women than men ( Table 1) . Serum proportions of EPA and DHA were highly correlated (r=0.72), while weaker inverse correlations were observed between LA and the two VLC n-3 PUFA ( Supplementary   Table 1 ). Correlations between serum ALA and the other PUFA were absent or weak (r 0.16).
During follow-up (median 14.5 y), 304 men and 180 women suffered a first CVD event.
By the end of the follow-up period (December 31, 2012), 191 women and 265 men had died.
Cancer (ICD10: C00-C99), CVD (ICD10: I00-I99), and respiratory diseases (ICD10: J00-J99),
were the most common causes of deaths and were responsible for 47% (54% in women and 42% in men), 25% (17% in women and 30% in men), and 7.0% (8.9% in women and 5.7% in men), respectively, of all deaths.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Serum CE EPA was inversely associated with incident CVD in women ( Table 2,   Supplementary Table 2 , Figure 1A -B), while DHA was associated with lower risk of incident CVD in women as well as in the whole population ( Table 2, Supplementary Tables 3, Figure 1C-D). After adjustment for potential confounders, a 1-SD increase in EPA and DHA (i.e., 1.0% and 0.2% of total FA, respectively) among women resulted in 21% and 26% lower risk of CVD, respectively ( Table 2) . When extreme quartiles were compared, women in the highest quartiles of EPA and DHA had 41% (adjusted HR 0.59, 95% CI 0.39-0.91) and 52% (adjusted HR 0.48, 95% CI 0.31-0.73) lower risk of CVD, respectively ( Supplementary Tables 2-3) . 
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EPA and DHA were inversely associated with all-cause mortality in the total population and in men and women separately ( Table 2, Supplementary Tables 2-3 , Figure 2A-D) . In the adjusted model, a 1-SD increment in EPA and DHA (approximately 1.0 % and 0.2% of total FA, respectively) was associated with approximately 20% lower mortality risk in men and women ( Table 2 ). In the total study population, individuals in the highest EPA and DHA quartiles had 42% (adjusted HR 0.58, 95% CI 0.43-0.77) and 40% (adjusted HR 0.60, 95% CI 0.46-0.79), respectively, decreased mortality risk than those in the lowest quartiles ( Supplementary Tables   2-3 ). In the total population, DHA was associated with lower risk of CVD mortality after adjustments for potential confounders, HR 0.75 (95% CI 0.59-0.94); and EPA tended to be inversely associated with CVD mortality, adjusted HR 0.80 (95% CI 0.64-1.00). Exclusion of participants with reported use of fish oil supplements (1% of the study population) did not affect any observed associations.
Linoleic acid (LA)
In the crude model, 1-SD (i.e., 4% of total FA) increment in LA was associated with lower risk of incident CVD in men (crude HR 0.88, 95% CI 0.78-0.99), and although the point estimate of association did not change substantially after adjustment for confounders, the association was no longer significant due to wider confidence interval ( Table 2) . After adjustment, no association between LA and CVD was observed in women and men, either when analyzed separately or combined ( Table 2 , Supplementary Table 4 ).
However, LA was associated (after adjustments) with decreased all-cause mortality in the total population and in men, but not in women ( Table 2 , Supplementary Table 4 , Figure 2E -F).
Men in the highest LA quartile had 41% lower (adjusted HR 0.59, 95% CI 0.41-0.85) mortality risk than those in the lowest quartile ( Supplementary Table 4 ). A 1-SD increment in LA (i.e., nversely associated with CVD mortality, adjusted HR 0.80 (95% CI 0.64-1.00). E E Exc xc xclu lu lusi si sion on on o o of f f participants with reported use of fish oil supplements (1% of the study population) did not affect any y ob ob obse se serv rv rved ed ed ass s soc oc ciations.
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-linolenic acid (ALA)
After adjustments for potential confounders, ALA was associated with higher risk of CVD among women (multivariable-adjusted HR 1.16; 95% CI 1.02-1.32 per 1-SD increment, i.e., 0.2% of total FA), but not men or the total population ( Table 5 ).
ALA was not associated with all-cause mortality ( Table 2 , Supplementary Table 5 ) or CVD mortality (data not shown).
Discussion
In this population-based cohort study, VLC n-3 PUFA (i.e., EPA and DHA) in serum CE was inversely associated with incident CVD in women and all-cause mortality in both sexes. The major dietary PUFA, LA, was inversely associated with all-cause mortality in men but not in women, and not associated with incident CVD. ALA was somewhat unexpectedly associated with increased risk of incident CVD among women. To our knowledge, this is the largest prospective cohort study with data on both serum PUFA and mortality in men and women.
There were sex-specific associations between serum n-3 PUFA and CVD, i.e., EPA and DHA were inversely associated with incident CVD only in women. Lower CVD risk at higher levels of circulating VLC n-3 PUFA derived from fish intake agrees with previous prospective studies (primary prevention) and with evidence from experimental studies and some clinical trials 8 , although the latter evidence from secondary prevention trials using fish oil supplements CVD mortality (data not shown). are somewhat inconsistent 28 . In one US cohort, serum DHA was inversely associated with heart failure in women only 18 , and in a recent meta-analysis, VLC n-3 PUFA biomarkers were inversely associated with CHD in women but not men 29 . In addition, another meta-analysis reported inverse associations between dietary VLC n-3 PUFA and stroke only in women 30 .
Disc c cus us ussi si sion on on
Discrepancies between men and women could be due to differences in overall dietary patterns 31 or fish intake, the latter currently reflected by higher serum DHA in women. However, previous studies have reported higher DHA concentrations in women than men, independent of intake 32, 33 .
Diverse protective effects in men and women may also involve e.g. platelet aggregation which may be inhibited in a sex-specific manner by VLC n-3 PUFA supplementation 34, 35 . Further research is needed to establish whether the sex-specific associations observed between various n-3 PUFA and outcomes are explained by differences in diet, biology (e.g., estrogens), PUFA metabolism, CVD etiology, or a combination of these.
Serum EPA and DHA showed inverse associations with all-cause mortality in both sexes.
In accordance, VLC n-3 PUFA in total plasma and plasma phospholipids were inversely associated with sudden cardiac death and with all-cause mortality, respectively, in two separate American cohorts 22, 36 . Interestingly, individual PUFA displayed different associations with diverse CVD-related deaths, e.g., DHA, but not EPA, was inversely associated with cardiac arrhythmia 22 . In serum CE, EPA and DHA were inversely associated with all-cause mortality risk in individuals with CHD 37 . However, no associations between serum VLC n-3 PUFA and all-cause or CVD mortality was observed in Swedish men with baseline measurements ~20 y before the present study. Apart from CVD protective effects of EPA and DHA, inverse associations of VLC n-3 PUFA and all-cause mortality may involve non-CVD diseases, which caused 75% of all deaths in the present study. For example, possible anti-inflammatory effects of esearch is needed to establish whether the sex-specific associations observed betw tw twee ee een n n va va vari ri riou ou ous s s n-both EPA and DHA 38 may be involved in reducing fatal events in many diseases 22 .
LA was not associated with incident CVD, but was strongly associated with lower risk of all-cause mortality in men. In a US cohort, plasma phospholipid LA was inversely associated with total and CVD mortality, with the strongest link to non-arrhythmic CHD mortality 23 . Such findings are in line with LDL-cholesterol lowering effects of LA, a likely contributing mechanism behind the inverse associations between circulating LA and CVD-related mortality observed in other cohorts 15, 16, 23 . Two studies have reported inverse associations between serum LA and mortality (all-cause and CVD-related) among men in Northern Europe 15, 39 . Such data also accord with an inverse association between dietary LA intake and CHD (events and deaths) as reported in a recent meta-analysis, although sex-specific associations were not directly investigated 4 . Although LA was associated with lower risk of CVD mortality in the total study population, the observed inverse association between LA and all-cause mortality in men may indicate a possible protection also of non CVD-related deaths, e.g., cancer 40 or respiratory disease 23 .
The observed moderately increased risk of CVD in women with the highest proportions of ALA does not accord with the overall literature and is for several reasons unlikely to reflect a detrimental effect of ALA per se on CVD risk. First, controlled secondary prevention trials have reported protective effects of increased ALA intake 41, 42 , or a trend towards decreased CVD risk in women 40 . A recent meta-analysis also reported a non-significant trend toward lower CVD risk at higher levels of ALA biomarkers 43 . Second, ALA in serum CE seems to be a weaker biomarker of dietary intake compared to LA, EPA, and DHA, as reported in Swedish men who was investigated during the same time period as in the present study 13 . A weak correlation between dietary and serum CE ALA could partly be attributed to the extensive beta-oxidation of as reported in a recent meta-analysis, although sex-specific associations were not t d d dir ir irec ec ectl tl tly y y ecommendations on PUFA intake are warranted. 
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